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Abstract Prostate cancer (CaP) is unique among all cancers in that when it metastasizes to bone, it typically forms
osteoblastic lesions (characterized by increased bone production). CaP cells produce many factors, including Wnts that
are implicated in tumor-induced osteoblastic activity. In this prospectus, we describe our research on Wnt and the CaP
bone phenotype. Wnts are cysteine-rich glycoproteins that mediate bone development in the embryo and promote bone
production in the adult. Wnts have been shown to have autocrine tumor effects, such as enhancing proliferation and
protecting against apoptosis. In addition,we have recently identified that CaP-producedWnts act in a paracrine fashion to
induce osteoblastic activity in CaP bone metastases. In addition to Wnts, CaP cells express the soluble Wnt inhibitor
dickkopf-1 (DKK-1). It appears that DKK-1 production occurs early in the development of skeletal metastases, which
results in masking of osteogenic Wnts, thus favoring osteolysis at the metastatic site. As metastases progress, DKK-1
expression decreases allowing for unmasking ofWnt’s osteoblastic activity and ultimately resulting in osteosclerosis at the
metastatic site. We believe that DKK-1 is one of the switches that transitions the CaP bone metastasis activity from
osteolytic to osteoblastic. Wnt/DKK-1 activity fits a model of CaP-induced bone remodeling occurring in a continuum
composed of an osteolytic phase, mediated by receptor activator of NFkB ligand (RANKL), parathyroid hormone-related
protein (PTHRP) and DKK-1; a transitional phase, where environmental alterations promote expression of osteoblastic
factors (Wnts) and decreases osteolytic factors (i.e., DKK-1); and an osteoblastic phase, inwhich tumor growth-associated
hypoxia results in production of vascular endothelial growth factor and endothelin-1, which have osteoblastic activity.
This model suggests that targeting both osteolytic activity and osteoblastic activity will provide efficacy for therapy of CaP
bone metastases. J. Cell. Biochem. 97: 661–672, 2006.  2005 Wiley-Liss, Inc.
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Prostate cancer (CaP) is the most frequently
diagnosed cancer inmen and the second leading
cause of cancer-related death amongmen in the
United States. The most common site of CaP
metastasis is the bonewithup to 84%of patients
demonstrating skeletal metastases [Abrams
et al., 1950]. The majority of cancers, such as
breast andmyeloma, produce areas of bone lysis
(osteolytic lesions) when they metastasize to
bone. Although there is consistently an osteoly-
tic component to CaP bone metastases, they
are typically characterized radiographically by
areas of increased bone production (i.e., osteo-
blastic). The mechanisms through which CaP
promotes aberrant bone remodeling are not
clearly defined. However, understanding this
pathophysiologymayhelpdesign therapies that
prevent the establishment of metastases in the
bone or that diminish progression of established
CaP metastases. Many groups have been
exploring the interactions between cancer and
bone with promising results. Recently, Wnts
have beendocumented to play an important role
in bone development and modulation of bone
production in adults. Based on these observa-
tions, we explored the role ofWnts as mediators
of CaP-induced osteoblastic activity. In this
prospectus, we will discuss our work on Wnts
and how that integrates with other osteoblastic
factors produced by CaP cells.
Wnt SIGNAL TRANSDUCTION
The Wnt proteins are a large family of
cysteine-rich glycoproteins currently consisting
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of 19 members. They function primarily during
development to control body axis symmetry and
branching morphogenesis [reviewed in Logan
and Nusse, 2004]. Wnts exert their biological
effects through three signaling pathways,
which are separated by their ability to stabilize
b-catenin (the canonical pathway). Canonical
Wnt proteins bind at the cell surface to a co-
receptor consisting of Frizzled (FZD) and low-
density lipoprotein receptor-related protein
(LRP) (Fig. 1). This union results in the
hyperphosphorylation of disheveled (DSH),
which blocks the activity of glycogen synthase
kinase 3b (GSK3b) through an unknown
mechanism [Yanagawa et al., 1995]. However,
GSK3-binding protein (GBP) was recently
implicated in the inhibition of GSK3b by
blocking its ability to bind the scaffold protein
Axin [Farr et al., 2000]. Inhibition of GSK
activity results in the stabilization and accu-
mulation ofb-cateninwhich, upon translocation
into the nucleus, serves as a co-factor for the T-
cell factor family of transcription factors (e.g., T-
cell factor (TCF) and Lymphoid enhancer factor
(LEF) [Van De Wetering et al., 1997]. The
closely related histone acetylases, p300 and
CBP, act as co-activators of b-catenin activity
[Hecht et al., 2000]. In the absence of Wnt
signals, cytoplasmic b-catenin is sequestered by
a complex consisting of Axin, the tumor sup-
pressor Adenomatous polyposis coli (APC), and
GSK3b [Kikuchi, 2000]. Phosphorylation by
GSK leads to ubiquitination and the subsequent
degradation of b-catenin. Non-canonical Wnts
also bind FZD to mobilize Dsh but do not
activate b-catenin/TCF [Yang, 2003]. Instead,
non-canonicalWnt proteins such asWnt5a lead
to the activation of protein kinase C and
calcineurin in the Wnt/Ca2þ pathway where
Wnt11 activates the small G-protein Rac and
Jun end-terminal kinase (JNK) in the planar
cell polarity pathway [Kuhl et al., 2000;Veeman
et al., 2003].
The activity of Wnt proteins is controlled by
soluble extracellular antagonists including
secreted FZD-related proteins (sFRP), Wnt
inhibitory factor-1 (WIF-1), Cerberus, and
Dickkopf (DKK) [Logan and Nusse, 2004]
(Fig. 2). sFRP, WIF-1, and Cerberus act as
competitive inhibitors of FZD by sequestering
Wnt factors and can, therefore, block both
canonical and non-canonical Wnt pathways.
DKK-1, in contrast, binds the Wnt co-receptors
LRP 5 and 6 to block canonical Wnt signaling
[Bafico et al., 2001; Mao et al., 2001]. Specifi-
cally, DKK-1 bridges LRPwith Kremin2 result-
ing in the removal of LRP from the cell surface
by endocytosis [Mao et al., 2002].
Wnts IN BONE BIOLOGY
Wnts in Bone Development
The use of knockout animals has demon-
strated an indispensable role for Wnt signaling
Fig. 1. The canonical Wnt signaling pathway. See text for description of pathway activity. APC,
Adenamatous polyposis coli; b-cat, b-catenin; CBP, CREB binding protein; CK, Casein kinase; Co-rep, co-
repressor;DSH,Disheveled; FZD, Frizzled;GBP,GSKbindingprotein;GSK,Glycogen synthase kinase; LEF,
lymphoid enhancer factor; P, phosphorus; TCF, T-cell factor. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
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in normal bone development. The spatial and
temporal expression ofWnt proteins is required
for limb bud initiation, dorsal-ventral pattern-
ing, and limb outgrowth [reviewed in Church
and Francis-West, 2002; Yang, 2003]. In parti-
cular, a requirement for canonical Wnt signal-
ing in limb initiation and patterning has been
revealed in animals carrying mutations in Wnt
antagonists DKK-1 and sFRP-1. DKK-1 null
mice develop fusion and duplication of digits;
whereas, overexpression of DKK-1 in the chick
results in distal truncation of the limb bud
[Mukhopadhyay et al., 2001; Grotewold and
Ruther, 2002]. The effect of DKK-1 deficiency in
the mouse may relate to a reduction in pro-
grammedcell death in the limb [Mukhopadhyay
et al., 2001; Grotewold and Ruther, 2002].
Indeed, the overexpression of DKK-1 in the
chick results in elevated programmed cell death
concomitant with the observed limb truncation
[Grotewold andRuther, 2002].Viewed together,
the data show that disruption of canonical Wnt
signaling results in significant limb defects in
the developing embryo. Direct evidence that
canonical Wnts participate in the bone biology
of adults has only recently been elucidated. It
was shown that adult mice deficient in the Wnt
antagonist sFRP-1 had increased trabecular
bone accrual without effects on cortical bone
[Bodine et al., 2004]. The demonstration that
defects in Wnt antagonists modulate bone
remodeling within adults is significant because
it defines a mechanism that can be exploited by
bone metastatic tumor cells to affect bone
biology.
Wnt Signaling and Regulation of Bone Mass
The first indication that Wnt signaling reg-
ulates bone mass came from a clinical study in
which inactivating mutations in the Wnt co-
receptor, LRP5, were linked to the autosomal
recessive disorder, osteoporosis pseudoglioma
syndrome [Gong et al., 2001], which is char-
acterized by decreased bone mass. Shortly
thereafter, it was found that gain-of-function
mutations in LRP5 cause a high bone mass
phenotype in humans [Boyden et al., 2002;
Little et al., 2002; Van Wesenbeeck et al.,
2003]. A link between LRP5 and bone formation
was supported by the phenotype of mice with
gain- or loss-of-function mutations in LRP5
[Kato et al., 2002; Babij et al., 2003]. Analysis
of mice containing mutations in LRP5, LRP6,
sFRP1, b-catenin, Wnt10b, or DKK2 suggests
that Wnt signaling regulates bone mass
through multiple mechanisms including osteo-
blast differentiation, proliferation, function,
survival, and coupling to osteoclast formation
[Pinson et al., 2000; Boyden et al., 2002; Babij
et al., 2003; Bodine et al., 2004; Bennett et al.,
2005; Day et al., 2005; Glass et al., 2005; Hill
et al., 2005; Holmen et al., 2005; Hu et al., 2005;
Fig. 2. Endogenous inhibitors of Wnt signaling. Soluble Frizzled related protein (sFRP) can sequester Wnt
so that it cannot bind to cell surface Frizzled (FZD). Kremen facilitates the binding of Dickkopf (DKK) to the
Low-density lipoprotein receptor-related protein (LRP),which results in blockingWnt’s access to LRP. [Color
figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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Li et al., 2005b] [for in depth reviews, see
Johnson, 2004; Westendorf et al., 2004].
Mechanisms by Which Wnt Signaling Increases
Bone Mass
Stimulation of osteoblast differentia-
tion. Compelling evidence from humans and
mice indicates that Wnt signaling increases
bone mass, at least in part through induction of
osteoblastogenesis [Bodine et al., 2004]. Analy-
sis of this observation with mesenchymal
precursor cells in vitro has resulted in contra-
dictory findings. For example, Wnt1 or Wnt3a
increase the earlymarker of osteoblastogenesis,
alkaline phosphatase, in ST2, C3H10T1/2, and
C2C12 cells [Gong et al., 2001; Rawadi et al.,
2003; Jackson et al., 2005], and expression of
Wnt10b or dominant stable b-catenin is suffi-
cient to stimulate the full program of osteoblas-
togenesis in ST2 cells including mineralization
[Bennett et al., 2005]. In contrast, exposure of
adult human mesenchymal cells to Wnt3a
inhibits nodule formation [Boland et al., 2004],
and exposure to Wnt3a or the GSK3 inhibitor
lithium chloride inhibits dexamethasone-
induced osteogenesis [De Boer et al., 2004].
These seemingly contradictory observations
could be due to differences in cell models (the
spectrum of receptors expressed, or other
unknown factors including differences in
mechanism between species) or reflect a tem-
poral importance of Wnt signaling in osteoblast
differentiation. Recent evidence suggests that
disruption ofWnt signaling through the expres-
sion of DKK-1 and 2 blocked osteoblast differ-
entiation in immature osteoblasts but was
required to promote terminal differentiation in
late stage osteoblasts [Li et al., 2005b; van der
Horst et al., 2005].
Mesenchymal stem cells have the potential to
differentiate into a number of cell types and
considerable evidence now indicates that Wnt
signaling stimulates osteoblastogenesis and
represses differentiation to alternative cell fates
such as the adipocyte [Nuttall and Gimble,
2004].Anegative feedback relationshipbetween
osteoblastogenic and adipogenic transcription
factors is operative in mesenchymal precursors.
For example, activation of PPARg represses
expression and activity of Runx2 [Jeon et al.,
2003] and expression of the osteoblastogenic
transcription factor Msx2 inhibitsthe ability
of C/EBPa to increase expression of PPARg
[Cheng et al., 2003]. Moreover, activation of
Wnt signaling suppresses expression of adipo-
genic transcription factors such as PPARg and
C/EBPa, and increases expression of osteoblas-
togenic transcription factors such as Runx2,
Dlx5, and Osterix [Bennett et al., 2005]. Con-
sistent with this observation, expression of
Runx2 increases in the long bone of sFRP1
null mice, and expression of Runx2 is enhanced
by several canonical Wnts in vitro, perhaps
through direct binding of a b-catenin/TCF
complex to the Runx2 promoter [Gaur et al.,
2005]. Therefore, it appears that Wnt signaling
disrupts the balance between osteoblastogenic
and adipogenic transcription factors to induce
differentiation of mesenchymal precursors into
osteoblasts.
Regulation of osteoblast proliferation
and apoptosis. Wnt signaling may also
increase number of osteoblasts by regulating
their proliferation and/or apoptosis. It is well
known that Wnts stimulate proliferation [Reya
et al., 2003; Willert et al., 2003; Zechner et al.,
2003] of some cell types, including hematopoie-
tic- and neuronal-precursors, and that Wnts
inhibit apoptosis of other cell types [Chen et al.,
2001; Longo et al., 2002; Hwang et al., 2004;
Kennell and MacDougald, 2005] including pre-
adipocytes. Analyses of mice with altered Wnt
signaling provide some support for each of these
two mechanisms. For example, LRP5 null mice
show decreased proliferation of osteoblast and
progenitor cells but no obvious differences in
apoptotic index [Kato et al., 2002]. However,
apoptosis of osteocytes and osteoblasts was
reduced in mice with activating LRP5 muta-
tions and in mice devoid of sFRP1 [Babij et al.,
2003; Bodine et al., 2004]. These in vivo
observations are supported by in vitro studies
suggesting that canonical Wnt signaling
increases growth rate of undifferentiated and
proliferating precursor cell population and
inhibits apoptosis [Rawadi et al., 2003; Boland
et al., 2004; De Boer et al., 2004; Derfoul et al.,
2004]. Although effects of Wnt on proliferation
may involve induction of c-myc and cyclin D,
this mechanism has not been evaluated speci-
fically in osteoblasts. Similarly, induction of
growth factor release inhibits apoptosis in other
cellmodels [Chen et al., 2001; Longo et al., 2002]
but has not been evaluated for osteoblasts.
Thus, in addition to induction of osteoblastogen-
esis, Wnt signaling may increase total number
of osteoblasts by stimulation of proliferation
and survival of osteoblasts.
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Induction of osteoblast activity. Wnt
signaling may also stimulate bone formation
by increasing the mineralizing activity of
osteoblasts. Consistent with this hypothesis,
activation of b-catenin in osteoblasts specifi-
cally increases expression of type I collagen (the
major protein component of the bone extracel-
lular matrix), although basal expression of type
I collagen is not influenced by loss of b-catenin
[Glass et al., 2005]. Furthermore, fatty acid
binding protein (FABP)4-Wnt10b transgenic
mice have increased mineral apposition rate
without changes in surface osteoblast number
[unpublished data and Bennett et al., 2005],
suggesting that Wnt signaling increases osteo-
blast activity in this context.
Inhibition of osteoclast differentia-
tion. In addition to increasing bone formation,
Wnt signaling could also increase bone mass by
decreasing bone resorption. Indeed, there is
compelling evidence that Wnt signaling in
osteoblasts represses differentiation of bone
resorbing osteoclasts [Glass et al., 2005; Hol-
men et al., 2005]. Although there were no
significant difference in number and activity of
osteoclasts in LRP5 null or FABP4-Wnt10b
mice [unpublished data and Kato et al., 2002]
under some conditions, Wnt signaling in osteo-
blasts can regulate osteoclast differentiation.
While conditional deletion of b-catenin in
osteoblasts results in increased formation of
osteoclasts [Glass et al., 2005; Holmen et al.,
2005], increased Wnt signaling due to loss of
APC in osteoblasts causes decreased formation
of osteoclasts [Holmen et al., 2005]. Wnt signal-
ing inhibits osteoclast differentiation by
increasing osteoblast expression of osteoprote-
gerin, the decoy receptor for receptor activator
of NFkB ligand (RANKL), and an inhibitor of
osteoclastogenesis [Glass et al., 2005; Holmen
et al., 2005; Jackson et al., 2005].
BONE METASTASIS
Osteolysis Versus Osteosclerosis
Bone metastases can be quite debilitating.
Outgrowth of tumorswithin the bonemay cause
bone pain, fracture, and nerve compression/
paralysis each resulting in reduced quality of
life [Keller et al., 2001]. The bone is a frequent
site of soft tissue tumor metastasis. Typically
metastases target the trabecular bone (also
called cancellous) of the axial skeleton (e.g.,
spine, ribs, pelvis). For some tumor types,
including breast, prostate, and melanoma,
metastasis to the bone occurs with high fre-
quency. In CaP, for example, recent autopsy
data suggest that greater than 80% of men who
die of CaP have metastatic disease within the
bone, typically in the trabecular bone of the
pelvis, femur, and vertebral bodies [Bubendorf
et al., 2000]. A great deal of research effort has
focused on uncovering the mechanisms that
lead to bone metastasis [reviewed in Roodman,
2004]. An emerging area is concerned with how
tumor cells alter the bone to yield a bone-
destroying (osteolytic) or bone-forming (osteo-
blastic) lesion [Logothetis and Lin, 2005]. A
variety of factors are implicated in production of
osteolytic lesions. Parathyroid hormone related
protein (PTHrP) has been shown in vivo to
enhance the formation of osteolytic metastases
presumably through induction of osteoclast
activity [Boyce et al., 1999].We and others have
shown that osteolytic activity promotes the
development of tumor growth in bone and that
blocking bone resorption through inhibition of
RANKL activity, a requisite factor for osteo-
clastogenesis, prevents the establishment of
osteolytic tumors within the bone [Morony
et al., 2001; Zhang et al., 2001, 2003] and that
bone turnover due to osteolytic activity pro-
motes the development of tumor growth in bone
[Corey et al., 2003; Schneider et al., 2005]. At
present, it is unclear if the requirement for
osteoclastic activity reflects a need to debulk the
bone to permit the seeding of tumor cells or
whether bone resorption is needed to liberate
growth factors that promote tumor develop-
ment. It has been suggested that the osteolytic
activity releases growth factors from the bone
matrix, which then further enhance the cancer
cell growth and cancer-induced osteolytic activ-
ity in a continuing vicious cycle [Mundy, 1997;
Guise, 2000]. CaP is unique in that prostate
boney lesions are predominately osteoblastic in
nature with underlying osteolytic areas [Keller
et al., 2001]. A variety of factors have been
implicated in the ability of CaP to induce
osteoblastic lesions including insulin-like
growth factor [Fizazi et al., 2003], endothelin-1
[Nelson et al., 2003], bone morphogenetic
proteins [Dai et al., 2005], adrenomedullin
[Chirgwin et al., 2004], andvascular endothelial
growth factor [Dai et al., 2004; Rubin et al.,
2004].Most likely cancer-induced dysfunctional
bone remodeling involves a variety of osteoblas-
tic factors working in concert. However, prior to
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understandinghowall these factors integrate at
the metastatic site, it may be useful to under-
stand the individual role each factor may play.
Accordingly, we sought to explore the role of
Wnts in the biology of bone metastasis because
of their important role in osteoblast function.
Role of Wnts in Bone Metastasis
Wnts can have both autocrine effects, such as
directly influencing tumor growth and survival,
and paracrine effects, such as modulating bone
cell growth anddifferentiation. Thus,Wntsmay
impact the development of metastasis at many
steps along the metastatic cascade from pri-
mary tumor progression through induction of
the metastatic phenotype at the distant site.
Autocrine Wnt signaling and can-
cer. The role of canonical Wnt signaling in
tumor development of colorectal cancer (CRC)
has been well established [reviewed in Giles
et al., 2003]. The lesions that alter the Wnt
signaling pathway are downstream of Wnt
itself. In CRC, loss of heterozygosity in APC
occurs in over 85% of all sporadic forms of CRC
and nearly all familial adenomatosis polyposis
(FAP) cases [Giles et al., 2003]. In an additional
10% of CRC cases, mutations in the regulatory
region of b-catenin are found [Giles et al., 2003].
Both APC and b-catenin mutations lead to
the stabilization of b-catenin and the inap-
propriate expression of TCF-regulated genes
within the tumor cell. These gene products,
which have obvious implications to tumor
development and progression, include the tran-
scription factor c-Myc [He et al., 1998], the cell
cycle regulatory protein cyclin-D1 [Shtutman
et al., 1999], the angiogenic chemokine IL-8
[Levy et al., 2002], and the proteasesmatrilysin
and MMP7 [Brabletz et al., 1999; Crawford
et al., 1999].
In addition to these classical alterations in the
canonical Wnt signaling pathway, there is
growing evidence that b-catenin may become
activated in tumor cells through cross-talk with
non-Wnt signal transduction pathways. These
pathways may have relevance to bone metas-
tasis because they have been shown in vitro to
become active in bone metastatic tumor cells
such as breast and prostate. One example is
the receptor tyrosine kinase (RTK) c-Met,
which is overexpressed in bone metastases
of CaP [Humphrey et al., 1995; Pisters et al.,
1995; Hall et al., 2004]. c-Met can activate, in a
cell-type-specific manner, invasion, survival,
proliferation, morphogenesis, and angiogenesis
[reviewed in Jiang et al., 1999]. b-Catenin was
shown to physically associatewith c-Met in both
primary rat hepatocytes and human CRC cells
[Herynk et al., 2003]. Hepatocyte growth factor
(HGF), the principle ligand for c-Met, was found
to induce the nuclear translocation of b-catenin,
thus placing it in a position to participate in
gene transcription [Monga et al., 2002]. The
androgen receptor (AR) has also been shown to
directly interact with and mediate nuclear
translocation of b-catenin in CaP cells resulting
in induction of AR-dependent gene transcrip-
tion [Mulholland et al., 2002; Cronauer et al.,
2005]. A third example of cross talk is oncogenic
K-ras that recently was shown to stimulate
expression of Wnt target genes through the
inhibition of GSK3b by phosphatidylinostiol
3-kinase (PI 3-K) [Li et al., 2005a]. Although
c-Met, AR, andK-ras providenovelmechanisms
for the nuclear translocation of b-catenin, these
novel pathways have yet to be shown to operate
in vivo within bone metastases.
In addition to proliferation and survival,
canonical Wnt signaling within the metastatic
CaP cell may promote osteomimicry. Osteomi-
micry is a phenomenon described in CaP cells
where the tumor cell acquires properties of
osteoblasts [Koeneman et al., 1999]. For exam-
ple, CaP cells have been shown to express the
bone matrix protein osteopontin (OPN), the
OPN receptor CD44, and the bone-specific
transcription factor RUNX2 (Cbfa1/AML3)
[Koeneman et al., 1999]. We have also shown
that bone metastatic C4-2B CaP cells have
the ability to produce mineralized matrix
in vitro [Lin et al., 2001]. Wnts may mediate
osteomimicry in that both OPN and CD44 are
Wnt regulated genes and, as discussed below,
canonical Wnts stimulate osteoblast minerali-
zation and differentiation [Wielenga et al.,
1999; Muller et al., 2002]. Thus, osteomimicry
could represent an autocrine function of cano-
nical Wnt signaling that may contribute to the
osteoblastic nature of CaP boney lesions.
Paracrine Wnt signaling in cancer. The
previous section outlined how inappropriate
Wnt activity within a tumor cell can promote
tumor development and metastasis. Whether
canonical Wnt signaling within a tumor cell
mediates bone metastasis, however, is still
under investigation. Accumulating evidence
suggests that tumor-derived Wnt factors and
antagonists affect bone cell biology that may
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determine whether the resulting lesion is
osteolytic or osteoblastic in nature.
Wnt signaling has been implicated in limb
development, skeletal outgrowth, and in the
control of bone mass. However, until recently,
direct evidence that Wnt factors contribute to
the bone phenotype of metastatic tumor cells in
vivo was lacking. cDNA microarray and RT-
PCR analysis has demonstrated that both
breast and PCa cells express the message for
multiple Wnts, including but not limited to
Wnt2, Wnt5a, and Wnt7b [Huguet et al., 1994;
Lejeune et al., 1995]. To establish a role forWnts
in CaP bone metastasis, we, therefore, chose to
modulate canonicalWnt activity by altering the
expression of theWnt antagonist DKK-1, which
can regulate the activity of multiple canonical
Wnts. The strategy of using overexpression of
Wnt antagonists to block Wnt activity in the
adult animal has recently been demonstrated
and shown to affect both the growth of intes-
tinal epithelial cells and bone mineral density
[Bodine et al., 2004; Kuhnert et al., 2004].
Specifically, adenovirus-mediated transfer of
DKK-1 inhibited the proliferation in small
intestine leading to crypt degeneration where
knockout of sFRP-1 prolonged the accrual of
trabecular bone in adult mice [Bodine et al.,
2004; Kuhnert et al., 2004].
The suggestion that Wnt antagonists may
affect bone metastases was first described in
patients with multiple myeloma [Tian et al.,
2003]. Multiple myeloma is a hematopoietic
tumor that metastases to the bone to produce
highly osteolytic lesions. In these patients,
the expression ofDKK-1was found in osteolytic
foci, thus suggesting that blocking canonical
Wnt signaling through DKK-1 promoted the
osteolytic phenotype. Consistent with this
observation, we found that DKK-1 was exclu-
sively and abundantly expressed in human
PC-3 CaP cells, which are very osteolytic,
compared to other human CaP cell lines
(LNCaP, C4-2B, DuCaP, VCaP, LuCaP23.1,
and LuCaP 35), which produce mixed lytic/
blastic lesions [Hall et al., 2005]. When injected
into themarrow space of the tibia (intraosseous
injection), PC-3 cells produce highly osteolytic
lesions but paradoxically express the RNA
for numerous Wnts including Wnts 2, 3a, 5b,
7a, 7b, 10b, and 16. This led us to query if
DKK-1 blocked endogenous Wnt activity,
thus preventing the formation of osteoblastic
metastases.
To test this hypothesis, we inhibited Wnt
activity in the mixed osteoblastic/osteolytic C4-
2B CaP cell line through stable overexpression
of DKK-1. This manipulation resulted in a
significant increase in osteolysis (as measured
by bone mineral density and percent osteolytic
area) following intraosseous injection compared
to vector control cells, which produce a mixed
osteolytic and osteoblastic lesion similar to that
observed in human CaP patients [Hall et al.,
2005]. In a corollary study, we inhibited DKK-1
expression in the PC-3 cell line using a shRNA.
This resulted in inhibition of PC-3 growth in
the bone and an associated decrease of PC3-
induced osteolytic lesions (unpublished data).
This observation, as discussed above,may reflect
aneed for initial osteolysis to establish the tumor
within the bone. If this is true andyetCaPboney
Fig. 3. Model of Wnts paracrine role in prostate cancer (CaP)
bone metastases. CaP cells have both osteolytic and osteoblastic
potential. Wnts are one of several osteoblastic factors produced
by CaP cells. However, early in skeletal metastasis, the CaP cells
express DKK-1 which blocks osteoblastic Wnt activity, thus
favoring an osteolytic phenotype (left panel). As the metastasis
progresses and is exposed to growth factors from the resorbing
bone, its phenotype changes such that DKK-1 expression is
decreased and unmasks Wnt osteoblastic activity resulting in
osteosclerosis (right panel). [Color figure can be viewed in the
online issue,which is available atwww.interscience.wiley.com.]
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lesions are ultimately osteoblastic, then DKK-1
must at some point be switched off to allow bone
formation in CaP metastases (Fig. 3). These
data demonstrate, for the first time, that the
Wnt pathway contributes to the formation of
CaP osteoblasticmetastases in vivo and suggest
that DKK-1 functions as a molecular switch in
CaP that transitions the metastatic lesion from
an initial osteolytic to an osteoblastic response.
FINAL THOUGHTS
CaP metastasizes to the bone with high
frequency where it produces mixed osteoblas-
tic/osteolytic lesions. Although the precise
mechanisms mediating both the organ specifi-
city andbonephenotype ofCaPbonemetastases
are unclear, there is increasing evidence that
canonical Wnt signaling could function both in
an autocrine and paracrine fashion to facilitate
tumor cell growth and osteoblast differentia-
tion. Moreover, the evidence suggests that
instead of a vicious cycle of ongoing osteolytic
activity, as is observed in breast cancer, that
CaP initially has osteolytic activity, which
transitions to osteoblastic activity as themetas-
tasis progresses (Fig. 4). We believe the regula-
tion of canonical Wnt signaling by DKK-1 may
act as a molecular switch mediating the transi-
tion from an osteolytic to an osteoblastic
response. Therefore, blocking DKK-1 activity
may prove to be a relevant therapeutic target in
the prevention of CaP bone metastasis.
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